论文部分内容阅读
目的观察灯盏细辛注射液治疗椎基底动脉供血不足(VBI)性眩晕的临床疗效和安全性。方法将64例患者随机分为对照组和治疗组,每组32例,两组患者均按病情需要常规给予脑细胞活化剂和口服肠溶阿司匹林片、尼莫地平片及西比灵胶囊等西药治疗。对照组用香丹注射液20 ml加生理盐水250 ml静脉滴注,每日1次;治疗组用灯盏细辛注射液40 ml加生理盐水250 ml静脉滴注,每日1次;两组疗程均为10 d。观察两组的临床疗效、平均脑血流速度和纤维蛋白原的变化及不良反应。结果治疗组临床疗效的总有效率为90.6%,优于对照组的68.8%,两组比较差异有统计学意义(P<0.05)。两组平均脑血流速度均较治疗前明显改善(P<0.05);且治疗组平均脑血流速度明显加快,优于对照组(P<0.05)。两组纤维蛋白原均较治疗前降低明显(P<0.05);且治疗组纤维蛋白原降低明显优于对照组(P<0.05)。结论灯盏细辛注射液治疗椎基底动脉供血不足性眩晕是安全及有效的。
Objective To observe the clinical efficacy and safety of Erigeron Breviscapus Injection in the treatment of Vertebrobasilar insufficiency (VBI) vertigo. Methods 64 patients were randomly divided into control group and treatment group, 32 cases in each group. Patients in both groups were given conventional brain cell activator and oral enteric-coated aspirin tablets, nimodipine tablets and xibiben capsules treatment. Control group with Xiangdan injection 20 ml plus saline 250 ml intravenous infusion, once daily; treatment group with Erigeronic Injection 40 ml plus saline 250 ml intravenous infusion 1 day; two treatment groups All 10 d. The clinical efficacy, mean cerebral blood flow velocity and changes of fibrinogen and adverse reactions in both groups were observed. Results The total effective rate in the treatment group was 90.6%, which was higher than that in the control group (68.8%). There was significant difference between the two groups (P <0.05). The average cerebral blood flow velocity in both groups was significantly improved compared with that before treatment (P <0.05). The mean cerebral blood flow velocity in the treatment group was significantly faster than that in the control group (P <0.05). The levels of fibrinogen in both groups were significantly lower than those before treatment (P <0.05). The reduction of fibrinogen in the treatment group was significantly better than that in the control group (P <0.05). Conclusion Erigeron breviscapus injection vertebrobasilar insufficiency vertigo is safe and effective.